Geneos Wealth Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Geneos Wealth Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-182	Closed	-$20.7K	–	2135
2022 Q4	$20.7K	Buy	+182	New	+$15.1K	﹤0.01%	1330
2022 Q3	–	Sell	-200	Closed	-$16K	–	2733
2022 Q2	$16K	Hold	200	–	–	﹤0.01%	1799
2022 Q1	$21K	Sell	200 -1,200	-86%	-$117K	﹤0.01%	1794
2021 Q4	$150K	Hold	1,400	–	–	0.01%	1000
2021 Q3	$153K	Hold	1,400	–	–	0.01%	980
2021 Q2	$134K	Sell	1,400 -130	-8%	-$12K	0.01%	1042
2021 Q1	$144K	Sell	1,530 -200	-12%	-$16.9K	﹤0.01%	1130
2020 Q4	$144K	Buy	+1,730	New	+$129K	0.01%	975

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geneos Wealth Management's HZNP Position: Q1 2023 in Review

Geneos Wealth Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 182 shares — an estimated $20.7K sold.

Geneos Wealth Management first reported a position in HZNP in Q4 2020 and held it in 8 quarters. The position peaked at $153K in Q3 2021. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Geneos Wealth Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Geneos Wealth Management sold 182 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $20.7K.
Geneos Wealth Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 8 quarters.
Geneos Wealth Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $153K in Q3 2021.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Geneos Wealth Management's 13F filing for Q1 2023, filed 25 Apr 2023.